Ind-Swift Laboratories (NSEI:INDSWFTLAB) - Aktienkurs, Nachrichten und Analyse

Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

INDSWFTLAB Aktienübersicht

Ind-Swift Laboratories Limited entwickelt, produziert und vertreibt pharmazeutische Wirkstoffe (APIs) und fortgeschrittene Zwischenprodukte in Indien.

Über das Unternehmen

INDSWFTLAB fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	5/6
Financial Health	5/6
Dividends	0/6

Belohnungen

Das Kurs-Gewinn-Verhältnis (1.5x) liegt unter dem Indian Markt (31x)

Die Erträge stiegen im vergangenen Jahr um 784.4%

Risikoanalyse

Hoher Anteil an nicht zahlungswirksame Erträge

Hat keine nennenswerte Marktkapitalisierung (₹6B)

Ind-Swift Laboratories Limited Wettbewerber

Albert David

BSE:524075

₹6.7b

Sakar Healthcare

NSEI:SAKAR

₹6.2b

Medicamen Biotech

BSE:531146

₹6.2b

Nectar Lifesciences

NSEI:NECLIFE

₹7.1b

Preisentwicklung & Leistung

Summary of all time highs, changes and price drops for Ind-Swift Laboratories
Historical stock prices
Current Share Price	₹114.69
52 Week High	₹138.45
52 Week Low	₹68.50
Beta	0.13
1 Month Change	6.10%
3 Month Change	7.44%
1 Year Change	64.43%
3 Year Change	-6.15%
5 Year Change	250.20%
Change since IPO	538.94%

Aktuelle Nachrichten und Updates

Shareholders In Ind-Swift Laboratories (NSE:INDSWFTLAB) Should Look Beyond Earnings For The Full Story

May 21

Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) Surges 26% Yet Its Low P/E Is No Reason For Excitement

Apr 13

Recent updates

Shareholders In Ind-Swift Laboratories (NSE:INDSWFTLAB) Should Look Beyond Earnings For The Full Story

May 21

Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) Surges 26% Yet Its Low P/E Is No Reason For Excitement

Apr 13

Here's Why Ind-Swift Laboratories (NSE:INDSWFTLAB) Can Manage Its Debt Responsibly

Dec 28

These 4 Measures Indicate That Ind-Swift Laboratories (NSE:INDSWFTLAB) Is Using Debt Reasonably Well

Jul 22

Ind-Swift Laboratories (NSE:INDSWFTLAB) Has A Somewhat Strained Balance Sheet

Jul 12

Did Business Growth Power Ind-Swift Laboratories' (NSE:INDSWFTLAB) Share Price Gain of 231%?

Feb 17

We're Not So Sure You Should Rely on Ind-Swift Laboratories's (NSE:INDSWFTLAB) Statutory Earnings

Dec 30

These 4 Measures Indicate That Ind-Swift Laboratories (NSE:INDSWFTLAB) Is Using Debt Extensively

Nov 11

Is Ind-Swift Laboratories (NSE:INDSWFTLAB) A Risky Investment?

Jun 27

Aktionärsrenditen

	INDSWFTLAB	IN Pharmaceuticals	IN Markt
7D	9.4%	3.7%	2.7%
1Y	64.4%	56.2%	44.1%

Rendite im Vergleich zur Industrie: INDSWFTLAB übertraf die Branche Indian Pharmaceuticals, die im vergangenen Jahr eine Rendite von 52.2 erzielte.

Rendite vs. Markt: INDSWFTLAB übertraf den Markt Indian, der im vergangenen Jahr eine Rendite von 34.5 erzielte.

Preisvolatilität

Is INDSWFTLAB's price volatile compared to industry and market?
INDSWFTLAB volatility
INDSWFTLAB Average Weekly Movement	8.2%
Pharmaceuticals Industry Average Movement	6.2%
Market Average Movement	6.8%
10% most volatile stocks in IN Market	9.9%
10% least volatile stocks in IN Market	4.5%

Stabiler Aktienkurs: INDSWFTLAB hatte in den letzten 3 Monaten keine nennenswerte Preisvolatilität.

Volatilität im Zeitverlauf: INDSWFTLABDie wöchentliche Volatilität (8%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1995	1,496	n/a	www.indswiftlabs.com

Ind-Swift Laboratories Limited entwickelt, produziert und vertreibt pharmazeutische Wirkstoffe (APIs) und fortgeschrittene Zwischenprodukte in Indien. Das Unternehmen bietet APIs in verschiedenen therapeutischen Bereichen an, darunter Makrolid-Antibiotika, Herz-Kreislauf-Mittel, Antihistaminika, Antidiabetika, Antipsychotika, Knochenresorptionshemmer, Antimigräne, Parkinson-Krankheit, Hyperparathyreodismus, Analgetika, Aromatasehemmer, Nootropika, Antidiarrhoika/Antiprotozoika, Anticholinergika, Sedativa, Hypnotika und Antineoplastika sowie verschiedene Produkte gegen ADHS-Symptome. Außerdem bietet es Referenzstandards und Verunreinigungen für Acamprosat-Calcium, Anastrozol, Aripiprazol, Atorvastatin-Calcium, Bexaroten, Cinacalcet-Hydrochlorid, Clopidogrel-Bisulfat, Clarithromycin, Ezetimib, Fexofenadin-Hydrochlorid, Imatinib-Mesylat, Ivabradin-Hydrochlorid, Ivabradin-Oxalat, Letrozol, Mecloxamin-Citrat, Naratriptan-Hydrochlorid, Nitazoxanid, Quetiapin, Ropinirol-Hydrochlorid, Rosuvastatin-Calcium, Saxagliptin-Monohydrat, Silodosin und Temozolomid sowie Auftragsforschung und -herstellung.

Ind-Swift Laboratories Limited's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Ind-Swift Laboratories im Vergleich zum Marktanteil des Unternehmens?
INDSWFTLAB grundlegende Statistiken
Marktanteil	₹6.77b
Gewinn(TTM)	₹4.21b
Umsatz(TTM)	₹12.81b

1.6x

Kurs-Gewinn-Verhältnis

0.5x

Kurs-Umsatz-Verhältnis

Ist INDSWFTLAB zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
INDSWFTLAB Gewinn- und Verlustrechnung (TTM)
Einnahmen	₹12.81b
Kosten der Einnahmen	₹6.61b
Bruttogewinn	₹6.19b
Sonstige Ausgaben	₹1.98b
Umsatz	₹4.21b

Zuletzt gemeldete Gewinne

Mar 31, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	71.24
Bruttomarge	48.36%
Nettogewinnspanne	32.86%
Schulden/Eigenkapital-Verhältnis	1.8%

Wie hat sich INDSWFTLAB auf lange Sicht entwickelt?

Historische Performance und Vergleiche

INDSWFTLAB Aktienübersicht

Belohnungen

Risikoanalyse

Ind-Swift Laboratories Limited Wettbewerber

BSE:524075

₹6.7b

NSEI:SAKAR

₹6.2b

BSE:531146

₹6.2b

NSEI:NECLIFE

₹7.1b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Shareholders In Ind-Swift Laboratories (NSE:INDSWFTLAB) Should Look Beyond Earnings For The Full Story

Full year 2024 earnings released: EPS: ₹71.24 (vs ₹8.06 in FY 2023)

New minor risk - Share price stability

Ind-Swift Laboratories Limited to Report Q4, 2024 Results on May 13, 2024

Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) Surges 26% Yet Its Low P/E Is No Reason For Excitement

Investor sentiment improves as stock rises 15%

Recent updates

Shareholders In Ind-Swift Laboratories (NSE:INDSWFTLAB) Should Look Beyond Earnings For The Full Story

Full year 2024 earnings released: EPS: ₹71.24 (vs ₹8.06 in FY 2023)

New minor risk - Share price stability

Ind-Swift Laboratories Limited to Report Q4, 2024 Results on May 13, 2024

Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) Surges 26% Yet Its Low P/E Is No Reason For Excitement

Investor sentiment improves as stock rises 15%

Synthimed Labs Private Limited agreed to acquire API and CRAMS business of Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) and Essix Biosciences Limited.

Third quarter 2024 earnings released: EPS: ₹3.29 (vs ₹4.65 in 3Q 2023)

Ind-Swift Laboratories Limited to Report Q3, 2024 Results on Feb 12, 2024

Here's Why Ind-Swift Laboratories (NSE:INDSWFTLAB) Can Manage Its Debt Responsibly

Second quarter 2024 earnings released: EPS: ₹5.36 (vs ₹4.29 in 2Q 2023)

Ind-Swift Laboratories Limited to Report Q2, 2024 Results on Nov 07, 2023

Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) agreed to acquire Ind-Swift Limited (BSE:524652).

Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) agreed to acquire Ind-Swift Limited (BSE:524652).

Synthimed Labs Private Limited agreed to acquire API and CRAMS business of Ind-Swift Laboratories Limited for INR 16.5 billion.

Ind-Swift Laboratories Limited, Annual General Meeting, Sep 30, 2023

Investor sentiment improves as stock rises 19%

First quarter 2024 earnings released: EPS: ₹2.92 (vs ₹3.36 in 1Q 2023)

Ind-Swift Laboratories Limited to Report Q1, 2024 Results on Aug 09, 2023

These 4 Measures Indicate That Ind-Swift Laboratories (NSE:INDSWFTLAB) Is Using Debt Reasonably Well

Group Head of Human Resources recently sold ₹3.3m worth of stock

Investor sentiment improves as stock rises 16%

Chief Accounts Officer recently sold ₹1.6m worth of stock

Full year 2023 earnings released: EPS: ₹8.06 (vs ₹0.36 loss in FY 2022)

Insufficient new directors

Third quarter 2023 earnings released: EPS: ₹4.65 (vs ₹2.71 in 3Q 2022)

Insider recently sold ₹1.2m worth of stock

Second quarter 2023 earnings released: EPS: ₹4.29 (vs ₹4.14 in 2Q 2022)

Insider recently sold ₹1.6m worth of stock

Ind-Swift Laboratories Limited to Report Fiscal Year 2023 Results on May 30, 2023

First quarter 2023 earnings released: EPS: ₹3.36 (vs ₹3.18 in 1Q 2022)

Ind-Swift Laboratories Limited, Annual General Meeting, Sep 30, 2022

Ind-Swift Laboratories Limited to Report Q1, 2023 Results on Aug 10, 2022

Full year 2022 earnings released: ₹0.36 loss per share (vs ₹0.53 loss in FY 2021)

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS ₹4.14 (vs ₹1.68 in 2Q 2021)

Investor sentiment deteriorated over the past week

Soft Air General Trading LLC agreed to acquire Ind-Swift Middle East FZ-LLC from Ind-Swift Laboratories Limited (BSE:532305) for approximately $2 million.

First quarter 2022 earnings released: EPS ₹3.18 (vs ₹0.77 in 1Q 2021)

High number of new directors

Ind-Swift Laboratories (NSE:INDSWFTLAB) Has A Somewhat Strained Balance Sheet

Full year 2021 earnings released: ₹0.53 loss per share (vs ₹4.28 loss in FY 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Insider recently sold ₹1.0m worth of stock

Independent Director has left the company

Insider recently sold ₹1.4m worth of stock

Investor sentiment improved over the past week

Insider recently sold ₹2.1m worth of stock

Did Business Growth Power Ind-Swift Laboratories' (NSE:INDSWFTLAB) Share Price Gain of 231%?

Third quarter 2021 earnings released: EPS ₹1.95 (vs ₹1.90 loss in 3Q 2020)

Ind-Swift Laboratories Limited to Report Q3, 2021 Results on Feb 12, 2021

Investor sentiment deteriorated over the past week

Ind-Swift Labs' Promoters Reportedly Sound Out PEs to Sell Their Stake

Senior Vice President of Procurement recently sold ₹2.7m worth of stock

Erträge & Einnahmen